| 1 |
Goto Y, Nakamura A, Ashida R, et al. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer [J]. Radiat Oncol, 2018; 13(1): 118.
|
| 2 |
Taylor R, Opfermann K, Jones BD, et al. Comparison of radiation treatment delivery for pancreatic cancer: Linac intensity-modulated radiotherapy versus helical tomotherapy [J]. J Med Imaging Radiat Oncol, 2012, 56(3): 332-337.
|
| 3 |
Dai ZT, Ma L, Cao TT, et al. Dosimetric and radiobiological comparison of treatment plan between CyberKnife and EDGE in stereotactic body radiotherapy for pancreatic cancer [J]. Sci Rep, 2021, 11(1): 4065.
|
| 4 |
Raturi VP, Tochinai T, Hojo H, et al. Dose-volume and radiobiological model-bbased comparative evaluation of the gastrointestinal toxicity risk of photon and proton irradiation plans in localized pancreatic cancer without distant metastasis [J]. Front Oncol, 2020, 10: 517061.
|
| 5 |
Stefanowicz S, Wlodarczyk W, Frosch S, et al. Dose-escalated simultaneously integrated boost photon or proton therapy in pancreatic cancer in an in-silico study: Gastrointestinal organs remain critical [J]. Clin Transl Radiat Oncol, 2020, 27: 24-31.
|
| 6 |
Liermann J, Naumann P, Hommertgen A, et al. Carbon ion radiotherapy as definitive treatment in non-metastasized pancreatic cancer: study protocol of the prospective phase II PACK-study [J]. BMC Cancer, 2020, 20(1): 947.
|
| 7 |
滕峰, 朱夫海, 任刚. 胰腺癌立体定向放疗中腹部危及器官解剖变化对剂量学的影响 [J]. 中日友好医院学报, 2021, 35(3): 150-153, 后插1.
|
| 8 |
Magallon-Baro A, Granton PV, Milder MTW, et al. A model-based patient selection tool to identify who may be at risk of exceeding dose tolerances during pancreatic SBRT [J]. Radiother Oncol, 2019, 141: 116-122.
|
| 9 |
Magallon-Baro A, Milder MTW, Granton PV, et al. Comparison of daily online plan adaptation strategies for a cohort of pancreatic cancer patients treated with SBRT [J]. Int J Radiat Oncol Biol Phys, 2021, 111(1): 208-219.
|
| 10 |
Tchelebi LT, Zaorsky NG, Rosenberg JC, et al. Reducing the toxicity of radiotherapy for pancreatic cancer with magnetic resonance-guided radiotherapy [J]. Toxicol Sci, 2020, 175(1): 19-23.
|
| 11 |
Placidi L, Romano A, Chiloiro G, et al. On-line adaptive MR guided radiotherapy for locally advanced pancreatic cancer: Clinical and dosimetric considerations [J]. Tech Innov Patient Support Radiat Oncol, 2020, 15: 15-21.
|
| 12 |
Patel JB, Revanur V, Forcione DG, et al. Endoscopic ultrasound-guided fiducial marker placement in pancreatic cancer: A systematic review and meta-analysis [J]. World J Gastrointest Endosc, 2020, 12(8): 231-240.
|
| 13 |
Kim SH, Shin EJ. Endoscopic ultrasound-guided fiducial placement for stereotactic body radiation therapy in pancreatic malignancy [J]. Clin Endosc, 2021, 54(3): 314-323.
|
| 14 |
Imaizumi A, Araki T, Okada H, et al. Transarterial fiducial marker implantation for CyberKnife radiotherapy to treat pancreatic cancer: an experience with 14 cases [J]. Jpn J Radiol, 2021, 39(1): 84-92.
|
| 15 |
Pollom EL, Alagappan M, von Eyben R, et al. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity [J]. Int J Radiat Oncol Biol Phys, 2014, 90(4): 918-925.
|
| 16 |
Tchelebi LT, Lehrer EJ, Trifiletti DM, et al. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis [J]. Cancer, 2020, 126(10): 2120-2131.
|
| 17 |
Teng F, Meng L, Zhu F, et al. Dosimetric feasibility on hypofractionated intensity-modulated radiotherapy and simultaneous integrated boost for locally advanced unresectable pancreatic cancer with helical tomotherapy [J]. J Gastrointest Oncol, 2021, 12(2): 496-506.
|
| 18 |
Mazzarotto R, Simoni N, Guariglia S, et al. Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar [J]. Front Oncol, 2020, 10: 600940.
|
| 19 |
Rao AD, Shin EJ, Meyer J, et al. Evaluation of a novel absorbable radiopaque hydrogel in patients undergoing image guided radiation therapy for borderline resectable and locally Advanced pancreatic adenocarcinoma [J]. Pract Radiat Oncol, 2020, 10(6): e508-e513.
|
| 20 |
Lee D, Komatsu S, Terashima K, et al. Surgical spacer placement for proton radiotherapy in locally advanced pancreatic body and tail cancers: initial clinical results [J]. Radiat Oncol, 2021, 16(1): 3.
|
| 21 |
Kawaguchi H, Demizu Y, Mukumoto N, et al. Efficacy of spacers in radiation therapy for locally advanced pancreatic cancer: a planning study [J]. Anticancer Res, 2021, 41(1): 503-508.
|
| 22 |
Wang J, Xia T, Wang Y, et al. Long-term results of gamma ray-based stereotactic body radiotherapy in treatment of medically unfit or inoperable non-metastatic pancreatic adenocarcinoma [Abstract 3587] [J]. Int J Radiat Oncol, Bio, Phy, 2012, 84(Suppl. 3): S815-S816.
|
| 23 |
Henke LE, Olsen JR, Contreras JA, et al. Stereotactic MR-guided online adaptive radiation therapy (SMART) for ultracentral thorax malignancies: results of a phase 1 trial [J]. Adv Radiat Oncol, 2018, 4(1): 201-209.
|
| 24 |
Rossi G, Simoni N, Paiella S, et al. Risk adapted ablative radiotherapy after intensive chemotherapy for locally advanced pancreatic cancer [J]. Front Oncol, 2021, 11: 662205.
|
| 25 |
Reyngold M, O'Reilly EM, Varghese AM, et al. Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer [J]. JAMA Oncol, 2021, 7(5): 735-738.
|